Trial Profile
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms RaPsOdy
- Sponsors Coherus Biosciences
- 17 Jun 2017 Results of this and extension trial (see profile 258274) presented at the 18th Annual Congress of the European League Against Rheumatism
- 27 Sep 2016 According to a Coherus Biosciences media release, the company is on track for submission of a CHS-0214 Marketing Authorization Application (MAA) to the European Medicines Agency in the fourth quarter of 2016. Data from two phase III studies and two pivotal clinical pharmacokinetic studies will support the MAA.
- 13 Jul 2016 This trial was completed in Germany (end date: 27-04-2016), according to European Clinical Trials Database.